Introduction: This quiz collection on FDA enforcement—covering Establishment Inspection Reports (EIRs), Warning Letters, and Recalls—is designed for M.Pharm students to strengthen regulatory knowledge crucial for pharmaceutical practice. You will find focused questions on inspection types, inspectional outcomes (NAI/VAI/OAI), Form FDA 483 versus EIR, FDA correspondence such as Warning and Untitled Letters, and the principles and classification of product recalls. The questions emphasize practical regulatory decision-making, response timelines, corrective actions, and enforcement tools (consent decrees, seizures, injunctions). Use these MCQs to test recall, understand regulatory intent, and prepare for roles in quality assurance, regulatory affairs, and compliance management.
Q1. What is an Establishment Inspection Report (EIR)?
- A preliminary notification of inspection results given verbally during the exit interview
- The official written report prepared by an FDA investigator that documents the inspection, observations, and related evidence
- A public press release announcing a product recall
- A court order enforcing a consent decree
Correct Answer: The official written report prepared by an FDA investigator that documents the inspection, observations, and related evidence
Q2. Which document is typically issued to a firm at the end of an FDA inspection listing specific inspectional observations?
- Establishment Inspection Report (EIR)
- Warning Letter
- Form FDA 483
- Consent Decree
Correct Answer: Form FDA 483
Q3. Which inspectional classification indicates “Official Action Indicated” and often triggers regulatory enforcement such as Warning Letters or legal actions?
- NAI (No Action Indicated)
- VAI (Voluntary Action Indicated)
- OAI (Official Action Indicated)
- CAI (Corrective Action Indicated)
Correct Answer: OAI (Official Action Indicated)
Q4. What is the primary difference between a Form FDA 483 and an FDA Warning Letter?
- A 483 is issued by the Office of Chief Counsel while a Warning Letter is issued by the local investigator
- A 483 lists observations at inspection exit; a Warning Letter is an official written demand for corrective action when initial responses are inadequate
- A 483 is a public document posted on FDA’s website, while Warning Letters are always confidential
- There is no difference; both are legal enforcement actions filed in court
Correct Answer: A 483 lists observations at inspection exit; a Warning Letter is an official written demand for corrective action when initial responses are inadequate
Q5. Which recall class describes a situation where use of or exposure to a violative product is not likely to cause adverse health consequences?
- Class I
- Class II
- Class III
- Class IV
Correct Answer: Class III
Q6. Which recall class represents a reasonable probability that use of or exposure to a violative product will cause serious adverse health consequences or death?
- Class I
- Class II
- Class III
- Class IV
Correct Answer: Class I
Q7. When FDA identifies significant deficiencies during an inspection, what is the typical recommended timeframe for a firm to provide a written response to a Form FDA 483?
- 24 hours
- 7 calendar days
- 15 business days
- 90 days
Correct Answer: 15 business days
Q8. What actions may FDA take when a firm fails to correct serious violations after issuance of a Warning Letter?
- Issue a Form FDA 483 again but take no further action
- Escalate to legal enforcement such as injunctions, seizures, or consent decrees
- Automatically approve new drug applications from the firm
- Transfer the inspection to a state authority with no further federal involvement
Correct Answer: Escalate to legal enforcement such as injunctions, seizures, or consent decrees
Q9. Who is primarily responsible for initiating a voluntary recall?
- The FDA District Court judge
- The manufacturer or distributor of the product
- The state public health department
- The product’s consumers through a class-action petition
Correct Answer: The manufacturer or distributor of the product
Q10. What is a Consent Decree in FDA enforcement context?
- A voluntary agreement between FDA and the firm to drop all inspectional findings
- A court-enforceable agreement that obligates a firm to take specific corrective actions under judicial oversight
- A routine administrative letter requesting additional documentation
- A classification system for recalls
Correct Answer: A court-enforceable agreement that obligates a firm to take specific corrective actions under judicial oversight
Q11. Which of the following best describes an “Untitled Letter” from FDA?
- A letter indicating imminent seizure of products
- A regulatory communication that addresses violations but is less serious than a Warning Letter and does not use the term “Warning”
- A final court judgment against a firm
- A public safety alert ordering a mandatory recall
Correct Answer: A regulatory communication that addresses violations but is less serious than a Warning Letter and does not use the term “Warning”
Q12. In the context of recalls, what is a “recall effectiveness check”?
- An FDA administrative fee assessed after a recall is filed
- An FDA-conducted or firm-performed verification activity to confirm that recalled product has been removed from commerce
- A legal hearing to determine recall classification
- A process of issuing a Form FDA 483 for recall-related issues
Correct Answer: An FDA-conducted or firm-performed verification activity to confirm that recalled product has been removed from commerce
Q13. Which of these is NOT an FDA enforcement tool?
- Warning Letter
- Consent Decree
- Product Reclassification by the manufacturer
- Seizure and Injunction
Correct Answer: Product Reclassification by the manufacturer
Q14. What should a robust response to a Form FDA 483 include from a pharmaceutical firm?
- A denial of all findings without evidence or corrective actions
- Timely acknowledgement, root cause analysis, corrective and preventive actions (CAPA), and timelines for completion
- Only a request for an extension to respond with no substantive content
- A public press release blaming suppliers
Correct Answer: Timely acknowledgement, root cause analysis, corrective and preventive actions (CAPA), and timelines for completion
Q15. Which FDA office typically reviews and issues Warning Letters for compliance violations?
- FDA Office of Criminal Investigations (OCI)
- FDA Office of Regulatory Affairs (ORA) in coordination with Center Office (e.g., CDER) or Office of Chief Counsel
- Centers for Medicare & Medicaid Services (CMS)
- The state attorney general’s office
Correct Answer: FDA Office of Regulatory Affairs (ORA) in coordination with Center Office (e.g., CDER) or Office of Chief Counsel
Q16. Which of the following findings is most likely to result in an OAI classification?
- Minor documentation typos in batch records with no product impact
- Inadequate sterility assurance leading to risk of contaminated sterile drug products
- Obsolete office furniture in administrative areas
- A single missing signature on an internal memo
Correct Answer: Inadequate sterility assurance leading to risk of contaminated sterile drug products
Q17. What immediate action does FDA often recommend when a product poses a serious health risk?
- Issuing an Untitled Letter
- Initiating or requesting a Class I recall with public notifications and removal from distribution
- Delaying action until the next routine inspection
- Recommending only internal corrective actions without public notification
Correct Answer: Initiating or requesting a Class I recall with public notifications and removal from distribution
Q18. After a recall is successfully executed and verified, how does a recall formally conclude?
- FDA never closes recalls; they remain open indefinitely
- The firm submits documentation and FDA may issue a recall termination when it determines the recall is adequately completed
- The recall automatically terminates after 7 days
- A recall is concluded only after a court order
Correct Answer: The firm submits documentation and FDA may issue a recall termination when it determines the recall is adequately completed
Q19. Which documentation is most critical to demonstrate traceability during a recall?
- Marketing brochures and advertising copy
- Distribution records, lot numbers, shipping logs, and customer contact information
- Employee vacation records
- Office lease agreements
Correct Answer: Distribution records, lot numbers, shipping logs, and customer contact information
Q20. What regulatory concept requires manufacturers to maintain effective quality systems to prevent violations that could lead to enforcement actions?
- Good Laboratory Practices (GLP) only
- Current Good Manufacturing Practice (cGMP) and quality system regulations
- Freedom to Operate (FTO)
- Patent term extension
Correct Answer: Current Good Manufacturing Practice (cGMP) and quality system regulations
